Press

PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease

Sep 14 • 3 min read

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), is pleased to provide an update on the development activities of the Company’s patented reformulated enteric coated version of orally bioavailable Cepharanthine (PD-001) as a potential treatment for oncology and infectious disease. The technical transfer and development activities with Genvion Corporation are well-underway in preparation…

Clearmind Medicine : Condensed Interim Consolidated Financial Statements – Form 6-K

Sep 13 • 27 min read

Condensed Interim Consolidated Financial Statements For The Three and Nine Months Ended July 31, 2023 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) July 31,2023 October 31,2022 Assets Current assets Cash and cash equivalents $ 3,847,259 $ 128,777 Other receivables 108,255…

FSD Pharma Announces Analyst Coverage Initiated by Singular Research

Sep 13 • 2 min read

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company“), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that Singular Research has initiated analyst coverage on FSD Pharma. A copy of the report can be obtained directly from the…

Psyched Wellness Lists Calm at All Central Market Locations, In the United States

Sep 13 • 2 min read

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the ‘Company’ or ‘Psyched’), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is excited to announce that Calm is continuing to expand within brick and mortar retailers by listing Calm at all Central Market locations. Central…

Psychedelic Drugs Market revenue to exceed USD 12 Billion by 2035, says Research Nester

Sep 12 • 2 min read

Leading psychedelic drugs market players include Research Nester are COMPASS Pathways plc, Silo Pharma, Inc., Numinus Wellness Inc., Cybin Inc., Mind Medicine Inc., Jazz Pharmaceuticals plc, PharmaTher Holdings Ltd., Janssen Pharmaceuticals, Inc., ATAI Life Sciences N.V. and Pfizer Inc.,. The global psychedelic drugs market size is predicted to grow at a CAGR of over ~…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435